Table 1

Implications of targeting statin treatment at four CHD risk levels, showing cost per life year gained at 4.5% annual CHD risk, and marginal cost per life year gained by extending treatment to 3.0%, 2.0%, and 1.5% annual CHD risk levels

  • RRR, relative risk reduction for all cause mortality. These sensitivity analyses do not apply to 4.5% and 1.5% CHD risk levels because these estimates were based directly on trial results.